Alector to Participate in Upcoming Healthcare Conferences
Alector will present fireside chats at Cantor and Morgan Stanley healthcare conferences, with live webcasts and 90-day replays for investors.
Rhea-AI Summary
Alector (ALEC) will participate in two investor healthcare conferences in New York in September 2026, each featuring a fireside chat with management.
The company joins the Cantor Global Healthcare Conference on September 10, 2026, at 2:10 p.m. ET and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, at 7:00 a.m. ET. Live webcasts and 90-day replays will be accessible via the Investors “Events & Presentations” page on Alector’s website.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 06 | Second-quarter earnings | Negative | -2.7% | Lower collaboration revenue outweighed narrower net loss and continued ABC platform development. |
| May 07 | First-quarter earnings | Negative | -13.9% | Trial discontinuation and quarterly loss accompanied reduced cash balance and ongoing ABC development. |
| Apr 29 | Phase 2 trial discontinuation | Negative | +3.0% | PROGRESS-AD was discontinued after interim analysis found it unlikely to meet its primary endpoint. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Alector's recent earnings announcements were followed by negative reactions, while the negative April clinical-trial announcement was followed by a positive reaction.
Key Terms
blood-brain barrier medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases, today announced that management will participate in the following upcoming investor conferences:
Cantor Global Healthcare Conference 2026 (New York, New York)
Thursday, September 10, 2026, at 2:10 p.m. ET, fireside chat
Morgan Stanley 24th Annual Global Healthcare Conference (New York, New York)
Tuesday, September 15, 2026, at 7:00 a.m. ET, fireside chat
A live webcast of each fireside chat will be available on the "Events & Presentations" page within the Investors section of the Alector website at http://investors.alector.com. Replays of the webcasts will be available on the Alector website for 90 days following the presentation dates.
About Alector
Alector is a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. Leveraging the principles of genetics, immunology, and neuroscience, the company is advancing a portfolio of programs that aim to remove toxic proteins, replace missing proteins, and restore immune and nerve cell function. Supported by biomarkers, Alector's product candidates seek to treat a range of indications, such as Alzheimer's disease and Parkinson's disease. The company is also developing Alector Brain Carrier (ABC), a proprietary blood-brain barrier platform, which is being applied to its preclinical and research pipeline. ABC aims to enhance the delivery of therapeutics, achieve deeper brain penetration and efficacy at lower doses, and ultimately improve patient outcomes while reducing costs. Alector is headquartered in South San Francisco, California. For more information, please visit www.alector.com.
Alector Contacts
Argot Partners (media)
David Rosen
646-461-6387
alector@argotpartners.com
Argot Partners (investors)
Laura Perry
212-600-1902
alector@argotpartners.com
